Renin-Angiotensin-System (RAS)-Acting Agents Global Market Report 2025
상품코드:1751094
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
레닌-안지오텐신계(RAS) 작용제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 5.8%의 성장률(CAGR)로 77억 3,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안의 성장은 맞춤형 치료에 대한 관심 증가, 복합제에 대한 수요 증가, 심혈관 연구에 대한 투자 확대, 신흥 시장에서의 의료 접근성 확대, 생활습관병 유병률 증가 등 여러 가지 요인에 기인하는 것으로 보입니다. 이 기간의 주요 동향으로는 AI를 활용한 의약품 개발, 나노기술을 활용한 약물전달, 맞춤형 의료의 발전, 안전한 임상 데이터를 위한 블록체인 활용, 고혈압 모니터링을 위한 웨어러블 바이오센서, 환자 모델링을 위한 디지털 트윈 기술 적용 등이 있습니다. 환자 모델링을 위한 디지털 트윈 기술 적용 등이 있습니다.
고혈압 유병률의 증가는 향후 몇 년 동안 레닌-안지오텐신계(RAS) 작용제 시장의 확대를 촉진할 것으로 예상됩니다. 고혈압은 동맥벽에 대한 혈액의 힘이 항상 너무 높은 만성질환입니다. 고혈압의 증가는 건강에 해로운 식습관, 특히 염분 및 가공식품이 많은 식습관이 주요 원인이며, 이는 혈압 상승 및 심혈관계 부담 증가의 원인이 되고 있습니다. 고혈압 완화에 도움을 줍니다. 혈관 확장을 촉진하고 혈압을 낮춤으로써 고혈압 관리에 도움을 줄 수 있습니다. 예를 들어, 2024년 10월 호주 통계청 발표에 따르면 2022년 호주인의 11.6%(300만 명)가 고혈압을 앓고 있으며, 남성(11.7%)과 여성(11.6%)은 비슷한 비율로 나타났습니다. 이처럼 고혈압 유병률의 증가가 RAS 작용제 시장의 성장을 견인하고 있습니다.
RAS 작용제 시장의 주요 업체들은 효능 개선, 부작용 최소화, 환자 순응도 향상, 고혈압, 심부전, 신장질환 치료를 위해 안지오텐신 전환효소(ACE) 억제제 등 신규 억제제 개발에 주력하고 있습니다. 혈관을 좁히는 물질인 안지오텐신 II로 전환하는 효소를 억제하여 혈압을 낮추는 작용을 합니다. 예를 들어, 2023년 11월 영국 제약사 Proveca Ltd.는 유럽위원회로부터 악멜디(에날라프릴 말레인산염) 경구용 분산정제의 소아과용 의약품 제조판매 승인(PUMA)을 받았습니다. 아크멜디는 ACE 억제제로 안지오텐신 I에서 안지오텐신 II로의 전환을 억제하여 혈관을 이완시키고 혈류를 개선하며 심장의 작업량을 감소시켜 소아 심부전을 치료하는 약물입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 레닌-안지오텐신계(RAS) 작용제PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 레닌-안지오텐신계(RAS) 작용제 시장 : 성장률 분석
세계의 레닌-안지오텐신계(RAS) 작용제 시장 실적 : 규모와 성장, 2019-2024
세계의 레닌-안지오텐신계(RAS) 작용제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 레닌-안지오텐신계(RAS) 작용제 전체 시장(TAM)
제6장 시장 세분화
세계의 레닌-안지오텐신계(RAS) 작용제 시장 : 약물 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
안지오텐신 전환효소(ACE) 억제제
안지오텐신 II 수용체 길항제(ARB)
레닌 억제제
알도스테론 길항제
기타 약물 클래스
세계의 레닌-안지오텐신계(RAS) 작용제 시장 : 적응증별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
고혈압
심부전
만성 신장병
당뇨병성 신증
관상동맥질환
세계의 레닌-안지오텐신계(RAS) 작용제 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
전문 클리닉
세계의 레닌-안지오텐신계(RAS) 작용제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
조사기관
제약회사
기타 최종사용자
세계의 레닌-안지오텐신계(RAS) 작용제 시장 안지오텐신 전환효소(ACE) 억제제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
캡토프릴
에날라프릴
리시노프릴
라미프릴
페린도프릴
세계의 레닌-안지오텐신계(RAS) 작용제 시장 안지오텐신 II수용체 길항제(ARB) 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
로사르탄
발사르탄
이르베사르탄
올메사르탄
텔미사르탄
세계의 레닌-안지오텐신계(RAS) 작용제 시장 레닌 억제제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
알리스키렌
세계의 레닌-안지오텐신계(RAS) 작용제 시장 알도스테론 길항제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
스피로노락톤
에플레레논
세계의 레닌-안지오텐신계(RAS) 작용제 시장, 기타 약물 클래스 유형별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
안지오텐신 수용체 네프릴리신 이중 억제제(ARNI)
엔도텔린 수용체 길항제
혈관 펩티다아제 억제제
무기질코르티코이드 수용체 길항제(MRA)
안지오텐신 수용체 길항제와 네프릴리신 억제제(ARNBI)
제7장 지역별·국가별 분석
세계의 레닌-안지오텐신계(RAS) 작용제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 레닌-안지오텐신계(RAS) 작용제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
레닌-안지오텐신계(RAS) 작용제 시장 : 경쟁 구도
레닌-안지오텐신계(RAS) 작용제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
Bayer AG Overview, Products and Services, Strategy and Financial Analysis
Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
AstraZeneca plc
Novartis AG
GSK plc
Teva Pharmaceutical Industries Ltd.
Boehringer Ingelheim GmbH
Sandoz International GmbH
Astellas Pharma Inc.
Bausch Health Companies Inc.
Aurobindo Pharma Limited
Cipla Limited
Dr. Reddy's Laboratories Ltd.
Biocon Limited
Daiichi Sankyo Company Limited
Glenmark Pharmaceuticals Ltd.
Torrent Pharmaceuticals Ltd.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
레닌-안지오텐신계(RAS) 작용제 시장 2029 : 새로운 기회를 제공하는 국가
레닌-안지오텐신계(RAS) 작용제 시장 2029 : 새로운 기회를 제공하는 부문
레닌-안지오텐신계(RAS) 작용제 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Renin-angiotensin system (RAS)-acting agents are a group of medications designed to regulate blood pressure, fluid balance, and vascular resistance by targeting different components of the renin-angiotensin system, which plays a vital role in cardiovascular and renal function. These agents are frequently prescribed for conditions such as hypertension, heart failure, and chronic kidney disease, either by blocking the production of angiotensin II or inhibiting its effects on blood vessels.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary classes of drugs in the renin-angiotensin system (RAS)-acting agents include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), renin inhibitors, aldosterone antagonists, and others. ACE inhibitors are medications that block the enzyme responsible for converting angiotensin I into angiotensin II, a substance that narrows blood vessels and raises blood pressure. They are used for various indications such as hypertension, heart failure, chronic kidney disease, diabetic nephropathy, and coronary artery disease. These drugs are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics, catering to various end users, including hospitals, research institutes, pharmaceutical companies, and others.
The renin-angiotensin-system (RAS)-acting agents market research report is one of a series of new reports from The Business Research Company that provides renin-angiotensin-system (RAS)-acting agents market statistics, including renin-angiotensin-system (RAS)-acting agents industry global market size, regional shares, competitors with a renin-angiotensin-system (RAS)-acting agents market share, detailed renin-angiotensin-system (RAS)-acting agents market segments, market trends and opportunities, and any further data you may need to thrive in the renin-angiotensin-system (RAS)-acting agents industry. This renin-angiotensin-system (RAS)-acting agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The renin-angiotensin-system (RAS)-acting agents market size has grown strongly in recent years. It will grow from$5.82 billion in 2024 to $6.17 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth during the historic period can be attributed to several factors, including the rising prevalence of hypertension, the increasing incidence of cardiovascular diseases, the growing aging population, heightened awareness about blood pressure management, strong support from clinical research, and regulatory approvals for new drugs.
The renin-angiotensin-system (RAS)-acting agents market size is expected to see strong growth in the next few years. It will grow to$7.73 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth during the forecast period can be attributed to several factors, including an increasing focus on personalized treatment, higher demand for fixed-dose combinations, greater investment in cardiovascular research, expanding healthcare access in emerging markets, and the rising prevalence of lifestyle-related diseases. Key trends during this period include AI-driven drug development, nanotechnology-based drug delivery, advancements in personalized medicine, the use of blockchain for secure clinical data, wearable biosensors for hypertension monitoring, and the application of digital twin technology for patient modeling.
The growing prevalence of hypertension is expected to drive the expansion of the renin-angiotensin system (RAS)-acting agents market in the coming years. Hypertension, or high blood pressure, is a chronic condition in which the force of blood against the artery walls is consistently too high. The rise in hypertension is largely due to unhealthy diets, particularly those rich in salt and processed foods, which contribute to higher blood pressure and increased strain on the cardiovascular system. RAS-acting agents help mitigate hypertension by regulating blood pressure through the inhibition of angiotensin II, a hormone that constricts blood vessels and increases fluid retention. By promoting vasodilation and reducing blood pressure, these agents help manage hypertension. For example, in October 2024, the Australian Bureau of Statistics reported that 11.6% (3.0 million) of Australians had hypertension in 2022, with similar rates observed for males (11.7%) and females (11.6%). Thus, the rising prevalence of hypertension is driving the growth of the RAS-acting agents market.
Key players in the RAS-acting agents market are focusing on developing novel inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors, to improve efficacy, minimize side effects, enhance patient compliance, and address hypertension, heart failure, and kidney diseases. ACE inhibitors work by lowering blood pressure through the blockage of the enzyme responsible for converting angiotensin I to angiotensin II, a substance that narrows blood vessels. For example, in November 2023, Proveca Ltd., a UK-based pharmaceutical company, received a grant from the European Commission for pediatric use marketing authorization (PUMA) for Aqumeldi (enalapril maleate) orodispersible tablets, which are indicated for the treatment of heart failure in children aged from birth to under 18 years. Aqumeldi, an ACE inhibitor, treats pediatric heart failure by preventing the conversion of angiotensin I to angiotensin II, thereby relaxing blood vessels, improving blood flow, and reducing the heart's workload.
In February 2023, AstraZeneca, a UK-based pharmaceutical company, acquired CinCor Pharma for $1.3 billion. Through this acquisition, AstraZeneca aims to strengthen its cardiorenal pipeline by adding CinCor's lead drug, baxdrostat (CIN-107), a selective aldosterone synthase inhibitor (ASI) designed to reduce blood pressure in treatment-resistant hypertension. CinCor Pharma, a U.S.-based biopharmaceutical company, is focused on developing RAS-acting agents, including baxdrostat, which targets resistant hypertension.
Major players in the renin-angiotensin-system (RAS)-acting agents market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sandoz International GmbH, Astellas Pharma Inc., Bausch Health Companies Inc., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Biocon Limited, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Ltd., and Torrent Pharmaceuticals Ltd.
North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in renin-angiotensin system (RAS)-acting agents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the renin-angiotensin system (RAS)-acting agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The renin-angiotensin system (RAS)-acting agents market consists of sales of enalapril, lisinopril, ramipril, and captopril. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Renin-Angiotensin-System (RAS)-Acting Agents Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on renin-angiotensin-system (ras)-acting agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for renin-angiotensin-system (ras)-acting agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The renin-angiotensin-system (ras)-acting agents market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Renin Inhibitors; Aldosterone Antagonists; Other Drug Classes
3. Renin-Angiotensin-System (RAS)-Acting Agents Market Trends And Strategies
4. Renin-Angiotensin-System (RAS)-Acting Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Renin-Angiotensin-System (RAS)-Acting Agents Growth Analysis And Strategic Analysis Framework
5.1. Global Renin-Angiotensin-System (RAS)-Acting Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Renin-Angiotensin-System (RAS)-Acting Agents Market Growth Rate Analysis
5.4. Global Renin-Angiotensin-System (RAS)-Acting Agents Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Renin-Angiotensin-System (RAS)-Acting Agents Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Renin-Angiotensin-System (RAS)-Acting Agents Total Addressable Market (TAM)
6.1. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Angiotensin-Converting Enzyme (ACE) Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Renin Inhibitors
Aldosterone Antagonists
Other Drug Classes
6.2. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hypertension
Heart Failure
Chronic Kidney Disease
Diabetic Nephropathy
Coronary Artery Disease
6.3. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Clinics
6.4. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Research Institutes
Pharmaceutical Companies
Other End-Users
6.5. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Captopril
Enalapril
Lisinopril
Ramipril
Perindopril
6.6. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Losartan
Valsartan
Irbesartan
Olmesartan
Telmisartan
6.7. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Renin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Aliskiren
6.8. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Aldosterone Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Spironolactone
Eplerenone
6.9. Global Renin-Angiotensin-System (RAS)-Acting Agents Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Renin-Angiotensin-System (RAS)-Acting Agents Market
9.1. China Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
9.2. China Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Renin-Angiotensin-System (RAS)-Acting Agents Market
10.1. India Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market
11.1. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
11.2. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Renin-Angiotensin-System (RAS)-Acting Agents Market
12.1. Australia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Renin-Angiotensin-System (RAS)-Acting Agents Market
13.1. Indonesia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market
14.1. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
14.2. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market
15.1. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
15.2. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Renin-Angiotensin-System (RAS)-Acting Agents Market
16.1. UK Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Renin-Angiotensin-System (RAS)-Acting Agents Market
18.1. France Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market
21.1. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
21.2. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Renin-Angiotensin-System (RAS)-Acting Agents Market
22.1. Russia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Renin-Angiotensin-System (RAS)-Acting Agents Market
23.1. North America Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
23.2. North America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Renin-Angiotensin-System (RAS)-Acting Agents Market
24.1. USA Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
24.2. USA Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Renin-Angiotensin-System (RAS)-Acting Agents Market
26.1. South America Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
26.2. South America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Renin-Angiotensin-System (RAS)-Acting Agents Market
27.1. Brazil Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market
28.1. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
28.2. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market
29.1. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market Overview
29.2. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Renin-Angiotensin-System (RAS)-Acting Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Renin-Angiotensin-System (RAS)-Acting Agents Market Competitive Landscape And Company Profiles
